Type III TGF-β receptor enhances colon cancer cell migration and anchorage-independent growth

Neoplasia

Volumn 13, Issue 8, 2011, Pages 758-770

  Gatza, Catherine E ^a   Holtzhausen, Alisha ^a   Kirkbride, Kellye C ^a   Morton, Allyson ^a   Gatza, Michael L ^a   Datto, Michael B ^a   Blobe, Gerard C ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN P21; PROTEIN P27; SMAD1 PROTEIN; SMAD2 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARCINOGENICITY; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VIVO STUDY; MIGRATION INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR GROWTH;

EID: 80051492302     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.11528     Document Type: Article

References (54)

1. Massague J (2008). TGFß in cancer. Cell 134, 215-230.
2. Pardali K and Moustakas A (2007). Actions of TGF-β as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta 1775, 21-62.
3. Esparza-Lopez J, Montiel JL, Vilchis-Landeros MM, Okadome T, Miyazono K, and Lopez-Casillas F (2001). Ligand binding and functional properties of betaglycan, a co-receptor of the transforming growth factor-ß superfamily. Specialized binding regions for transforming growth factor-ß and inhibin A. J Biol Chem 276, 14588-14596.
4. Gatza CE, Oh SY, and Blobe GC (2010). Roles for the type III TGF-β receptor in human cancer. Cell Signal 22, 1163-1174.
5. Kirkbride KC, Townsend TA, Bruinsma MW, Barnett JV, and Blobe GC (2008). Bone morphogenetic proteins signal through the transforming growth factor-ß type III receptor. J Biol Chem 283, 7628-7637.
6. Lopez-Casillas F, Wrana JL, and Massague J (1993). Betaglycan presents ligand to the TGF ß signaling receptor. Cell 73, 1435-1444.
7. Bernabeu C, Lopez-Novoa JM, and Quintanilla M (2009). The emerging role of TGF-β superfamily coreceptors in cancer. Biochim Biophys Acta 1792, 954-973.
8. Massague J (1998). TGF-β signal transduction. Annu Rev Biochem 67, 753-791.
9. Margulis V, Maity T, Zhang XY, Cooper SJ, Copland JA, and Wood CG (2008). Type III transforming growth factor-ß (TGF-β) receptor mediates apoptosis in renal cell carcinoma independent of the canonical TGF-β signaling pathway. Clin Cancer Res 14, 5722-5730.
10. You HJ, Bruinsma MW, How T, Ostrander JH, and Blobe GC (2007). The type III TGF-β receptor signals through both Smad3 and the p38 MAP kinase pathways to contribute to inhibition of cell proliferation. Carcinogenesis 28, 2491-2500.
11. Criswell TL and Arteaga CL (2007). Modulation of NFκB activity and E-cadherin by the type III transforming growth factor ß receptor regulates cell growth and motility. J Biol Chem 282, 32491-32500.
12. You HJ, How T, and Blobe GC (2009). The type III transforming growth factor-ß receptor negatively regulates nuclear factor κB signaling through its interaction with ß-arrestin2. Carcinogenesis 30, 1281-1287.
13. Mythreye K and Blobe GC (2009). The type III TGF-β receptor regulates epithelial and cancer cell migration through ß-arrestin2-mediated activation of Cdc42. Proc Natl Acad Sci USA 106, 8221-8226.
14. Vilchis-Landeros MM, Montiel JL, Mendoza V, Mendoza-Hernandez G, and Lopez-Casillas F (2001). Recombinant soluble betaglycan is a potent and isoformselective transforming growth factor-ß neutralizing agent. Biochem J 355, 215-222.
15. Xu Y and Pasche B (2007). TGF-β signaling alterations and susceptibility to colorectal cancer. Hum Mol Genet 16 Spec No 1, R14-R20.
16. Grady WM, Myeroff LL, Swinler SE, Rajput A, Thiagalingam S, Lutterbaugh JD, Neumann A, Brattain MG, Chang J, Kim SJ, et al. (1999). Mutational inactivation of transforming growth factor ß receptor type II in microsatellite stable colon cancers. Cancer Res 59, 320-324.
17. Howe JR, Bair JL, Sayed MG, Anderson ME, Mitros FA, Petersen GM, Velculescu VE, Traverso G, and Vogelstein B (2001). Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. Nat Genet 28, 184-187.
18. Kodach LL, Wiercinska E, deMiranda NF, Bleuming SA, Musler AR, Peppelenbosch MP, Dekker E, van den Brink GR, van Noesel CJ, Morreau H, et al. (2008). The bone morphogenetic protein pathway is inactivated in the majority of sporadic colorectal cancers. Gastroenterology 134, 1332-1341.
19. Neibergs HL, Hein DW, and Spratt JS (2002). Genetic profiling of colon cancer. J Surg Oncol 80, 204-213.
20. Xie W, Rimm DL, Lin Y, Shih WJ, and Reiss M (2003). Loss of Smad signaling in human colorectal cancer is associated with advanced disease and poor prognosis. Cancer J 9, 302-312.
21. Engle SJ, Hoying JB, Boivin GP, Ormsby I, Gartside PS, and Doetschman T (1999). Transforming growth factor ß1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis. Cancer Res 59, 3379-3386.
22. Hsu S, Huang F, Hafez M, Winawer S, and Friedman E (1994). Colon carcinoma cells switch their response to transforming growth factor ß1 with tumor progression. Cell Growth Differ 5, 267-275.
23. Warusavitarne J, McDougall F, de Silva K, Barnetson R, Messina M, Robinson BG, and Schnitzler M (2009). Restoring TGFß function in microsatellite unstable (MSI-H) colorectal cancer reduces tumourigenicity but increases metastasis formation. Int J Colorectal Dis 24, 139-144.
24. Friedman E, Gold LI, Klimstra D, Zeng ZS, Winawer S, and Cohen A (1995). High levels of transforming growth factor ß 1 correlate with disease progression in human colon cancer. Cancer Epidemiol Biomarkers Prev 4, 549-554.
25. Gregoire M, Garrigue L, Blottiere HM, Denis MG, and Meflah K (1992). Possible involvement of TGFß1 in the distinct tumorigenic properties of two rat colon carcinoma clones. Invasion Metastasis 12, 185-196.
26. Robson H, Anderson E, James RD, and Schofield PF (1996). Transforming growth factor ß1 expression in human colorectal tumours: an independent prognostic marker in a subgroup of poor prognosis patients. Br J Cancer 74, 753-758.
27. Yan Z, Kim GY, Deng X, and Friedman E (2002). Transforming growth factor ß1 induces proliferation in colon carcinoma cells by Ras-dependent, smad-independent down-regulation of p21cip1. J Biol Chem 277, 9870-9879.
28. Fujimoto K, Sheng H, Shao J, and Beauchamp RD (2001). Transforming growth factor-ß1 promotes invasiveness after cellular transformation with activated Ras in intestinal epithelial cells. Exp Cell Res 266, 239-249.
29. Motoyama K, Tanaka F, Kosaka Y, Mimori K, Uetake H, Inoue H, Sugihara K, and Mori M (2008). Clinical significance of BMP7 in human colorectal cancer. Ann Surg Oncol 15, 1530-1537.
30. Beck SE, Jung BH, Fiorino A, Gomez J, Rosario ED, Cabrera BL, Huang SC, Chow JY, and Carethers JM (2006). Bone morphogenetic protein signaling and growth suppression in colon cancer. Am J Physiol Gastrointest Liver Physiol 291, G135-G145.
31. Deng H, Makizumi R, Ravikumar TS, Dong H, Yang W, and Yang WL (2007). Bone morphogenetic protein-4 is overexpressed in colonic adenocarcinomas and promotes migration and invasion of HCT116 cells. Exp Cell Res 313, 1033-1044.
32. Hardwick JC, Van Den Brink GR, Bleuming SA, Ballester I, Van Den Brande JM, Keller JJ, Offerhaus GJ, Van Deventer SJ, and Peppelenbosch MP (2004). Bone morphogenetic protein 2 is expressed by, and acts upon, mature epithelial cells in the colon. Gastroenterology 126, 111-121.
33. Nishanian TG, Kim JS, Foxworth A, and Waldman T (2004). Suppression of tumorigenesis and activation of Wnt signaling by bone morphogenetic protein 4 in human cancer cells. Cancer Biol Ther 3, 667-675.
34. Deng H, Ravikumar TS, and Yang WL (2009). Overexpression of bone morphogenetic protein 4 enhances the invasiveness of Smad4-deficient human colorectal cancer cells. Cancer Lett 281, 220-231.
35. Deng X, Bellis S, Yan Z, and Friedman E (1999). Differential responsiveness to autocrine and exogenous transforming growth factor (TGF) ß1 in cells with nonfunctional TGF-β receptor type III. Cell Growth Differ 10, 11-18.
36. Yan Z, Deng X, and Friedman E (2001). Oncogenic Ki-ras confers a more aggressive colon cancer phenotype through modification of transforming growth factor-ß receptor III. J Biol Chem 276, 1555-1563.
37. Dong M, How T, Kirkbride KC, Gordon KJ, Lee JD, Hempel N, Kelly P, Moeller BJ, Marks JR, and Blobe GC (2007). The type III TGF-β receptor suppresses breast cancer progression. J Clin Invest 117, 206-217.
38. Finger EC, Turley RS, Dong M, How T, Fields TA, and Blobe GC (2008). TßRIII suppresses non-small cell lung cancer invasiveness and tumorigenicity. Carcinogenesis 29, 528-535.
39. Gordon KJ, Dong M, Chislock EM, Fields TA, and Blobe GC (2008). Loss of type III transforming growth factor ß receptor expression increases motility and invasiveness associated with epithelial to mesenchymal transition during pancreatic cancer progression. Carcinogenesis 29, 252-262.
40. Hempel N, How T, Dong M, Murphy SK, Fields TA, and Blobe GC (2007). Loss of betaglycan expression in ovarian cancer: role in motility and invasion. Cancer Res 67, 5231-5238.
41. Turley RS, Finger EC, Hempel N, How T, Fields TA, and Blobe GC (2007). The type III transforming growth factor-ß receptor as a novel tumor suppressor gene in prostate cancer. Cancer Res 67, 1090-1098.
42. Copland JA, Luxon BA, Ajani L, Maity T, Campagnaro E, Guo H, LeGrand SN, Tamboli P, and Wood CG (2003). Genomic profiling identifies alterations in TGFß signaling through loss of TGFß receptor expression in human renal cell carcinogenesis and progression. Oncogene 22, 8053-8062.
43. Gordon KJ, Kirkbride KC, How T, and Blobe GC (2009). Bone morphogenetic proteins induce pancreatic cancer cell invasiveness through a Smad1- dependent mechanism that involves matrix metalloproteinase-2. Carcinogenesis 30, 238-248.
44. Jakowlew SB (2006). Transforming growth factor-ß in cancer and metastasis. Cancer Metastasis Rev 25, 435-457.
45. Halaschek-Wiener J, Wacheck V, Schlagbauer-Wadl H, Wolff K, Kloog Y, and Jansen B (2000). A novel Ras antagonist regulates both oncogenic Ras and the tumor suppressor p53 in colon cancer cells. Mol Med 6, 693-704.
46. Edlund S, Landstrom M, Heldin CH, and Aspenstrom P (2002). Transforming growth factor-ß-induced mobilization of actin cytoskeleton requires signaling by small GTPases Cdc42 and RhoA. Mol Biol Cell 13, 902-914.
47. Yamazaki D, Kurisu S, and Takenawa T (2005). Regulation of cancer cell motility through actin reorganization. Cancer Sci 96, 379-386.
48. Bandyopadhyay A, Lopez-Casillas F, Malik SN, Montiel JL, Mendoza V, Yang J, and Sun LZ (2002). Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft. Cancer Res 62, 4690-4695.
49. Bandyopadhyay A, Zhu Y, Malik SN, Kreisberg J, Brattain MG, Sprague EA, Luo J, Lopez-Casillas F, and Sun LZ (2002). Extracellular domain of TGFß type III receptor inhibits angiogenesis and tumor growth in human cancer cells. Oncogene 21, 3541-3551.
50. Benhattar J, Losi L, Chaubert P, Givel JC, and Costa J (1993). Prognostic significance of K-ras mutations in colorectal carcinoma. Gastroenterology 104, 1044-1048.
51. Lopez-Casillas F, Payne HM, Andres JL, and Massague J (1994). Betaglycan can act as a dual modulator of TGF-β access to signaling receptors: mapping of ligand binding and GAG attachment sites. J Cell Biol 124, 557-568.
52. Bandyopadhyay A, Wang L, Lopez-Casillas F, Mendoza V, Yeh IT, and Sun L (2005). Systemic administration of a soluble betaglycan suppresses tumor growth, angiogenesis, and matrix metalloproteinase-9 expression in a human xenograft model of prostate cancer. Prostate 63, 81-90.
53. Lee JD, Hempel N, Lee NY, and Blobe GC (2010). The type III TGF-β receptor suppresses breast cancer progression through GIPC-mediated inhibition of TGF-β signaling. Carcinogenesis 31, 175-183.
54. Flatmark K, Maelandsmo GM, Martinsen M, Rasmussen H, and Fodstad O (2004). Twelve colorectal cancer cell lines exhibit highly variable growth and metastatic capacities in an orthotopic model in nude mice. Eur J Cancer 40, 1593-1598.